Editorial: Pharmacology and treatment methods for NAFLD in the context of diabetes

Front Endocrinol (Lausanne). 2022 Sep 1:13:1010485. doi: 10.3389/fendo.2022.1010485. eCollection 2022.

Authors

Mohamed Abu-Farha¹, Yong-Ho Lee^{2

3

4}, Jehad Abubaker¹

Affiliations

¹ Biochemistry and Molecular Biology Department, Dasman Diabetes Institute, Dasman, Kuwait.
² Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
³ Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, South Korea.
⁴ Department of Systems Biology, Glycosylation Network Research Center, Yonsei University, Seoul, South Korea.

No abstract available

Keywords: GLP1 agonist; NAFLD; SGLT2 (sodium-glucose cotransporter 2) inhibitor; liver fat; thiazolidinediones.

Publication types

Editorial

MeSH terms

Diabetes Mellitus, Type 2*
Humans
Non-alcoholic Fatty Liver Disease* / drug therapy